SRX3207 is primarily used as a selective inhibitor in biochemical research, particularly targeting specific signaling pathways involved in inflammation and immune response. It has shown potential in modulating protein-protein interactions that are critical in disease progression, making it a valuable tool in the development of therapeutic agents for autoimmune disorders and certain cancers. Due to its high selectivity, SRX3207 is employed in target validation studies to assess the functional impact of pathway inhibition without significant off-target effects. Its application extends to in vitro and in vivo models where precise control over molecular pathways is required for mechanistic studies.